Diltiazem

Diltiazemum

For medical students2 min readUpdated 2026-10-10

Diltiazem is an antiarrhythmic and antianginal drug classified as a benzothiazepine derivative. It combines both cardiac and vascular effects, largely resembling verapamil, but differs by having a faster onset of action and a distinct adverse effect profile.

Chemical classBenzothiazepine derivative

Onset of actionWithin 30 minutes (faster than verapamil)

BioavailabilityLow (20–35%) due to presystemic metabolism

PharmacodynamicsCombination of cardiac and vascular effects

1. Pharmacokinetics and Metabolism

Gastrointestinal absorption of the drug is quite high and complete. However, in clinical pharmacology, it is important not to confuse high absorption with high final bioavailability. For diltiazem (Diltiazemum), bioavailability remains extremely low, ranging from 20% to 35%.

The primary cause of this massive active substance loss is prominent presystemic metabolism (first-pass hepatic effect). In this regard, the drug is completely analogous to verapamil (Verapamilum). USMLE-style questions often try to trick you by listing renal clearance, enterohepatic circulation, or high plasma protein binding as reasons for low drug concentration in the blood. Do not fall for these traps: the correct answer is exclusively presystemic metabolism.

Regarding temporal parameters, the drug has specific characteristics:

Onset of action: The clinical effect develops within 30 minutes of administration, distinguishing it favorably from verapamil (diltiazem acts faster).
Half-life ($t_{1/2}$): Remains relatively short, ranging from 3 to 4 hours, which requires an appropriate dosing regimen.
Elimination: Metabolites are eliminated from the body predominantly via the gastrointestinal tract (feces).

2. Pharmacodynamics and Indications

To easily grasp the mechanism of action of diltiazem, recall the pharmacodynamics of verapamil. The mechanism of action of these two drugs is identical. Diltiazem is not limited to an isolated effect on the myocardium or peripheral vessels alone—it demonstrates a potent combination of cardiac and vascular effects.

When asked on an exam to compare the mechanism of action of various calcium channel blockers, remember that diltiazem is a functional analog of verapamil. Its profile is entirely unlike dihydropyridine derivatives, such as amlodipine (Amlodipinum) or nifedipine (Nifedipinum), which exert predominantly vascular effects and have minimal impact on the cardiac conduction system.

Based on this dual mechanism of action, the indications logically follow, mirroring those of verapamil:

Termination and prevention of angina attacks (coronary artery disease).
Treatment and rate control of various arrhythmias.

3. Adverse Effect Profile: Differences from Analogs

The most clinically relevant part of the topic for practice is adverse reactions. This is where diltiazem's primary clinical difference from verapamil lies. Despite sharing indications and mechanisms of action, their safety profiles have distinct individual traits that frequently form the basis of clinical vignettes.

While verapamil is traditionally associated with bradycardia, atrioventricular (AV) block, and marked constipation, diltiazem presents a different complication pattern. Patients taking diltiazem may experience the following adverse effects:

Hypotension — excessive blood pressure drop secondary to vasodilation.
Tachycardia — elevated heart rate (often a reflex response to lowered blood pressure).
Headache — a classic consequence of cerebral vessel dilation.
Edema — peripheral swelling characteristic of many drugs with a vascular component.
Muscle cramps — a very specific symptom that frequently serves as a test marker for this specific drug.

Mnemonic

To avoid confusing adverse effects on exams, remember the contrast: Verapamil "slows down" (bradycardia, AV block, constipation), whereas Diltiazem "speeds up and cramps" (tachycardia, muscle cramps, headache).

Frequently asked questions

What is the precise cellular mechanism of action of diltiazem?

The precise cellular mechanism of action of diltiazem involves the selective blockade of L-type voltage-gated calcium channels. The drug targets the $\alpha_1$-subunit of the channel, which acts as a voltage sensor. Normally, upon cell membrane depolarization, these channels open, allowing calcium ions to enter the cell and increase cytoplasmic concentration, triggering muscle contraction. By blocking this process, diltiazem exerts combined cardiac and vascular effects because L-type channels are located in cardiac myocytes and smooth muscle cells of resistance vessels.

What are the absolute contraindications to diltiazem administration?

Sources generally emphasize avoiding use in the presence of heart failure symptoms, significant left ventricular systolic dysfunction, sinoatrial or AV conduction abnormalities, and bradyarrhythmias. In chronic heart failure, diltiazem must be discontinued due to the high risk of severe bradycardia and myocardial depression.

Which drug classes are dangerous to combine with diltiazem?

Diltiazem should be used with caution or avoided when combined with:

Beta-blockers — co-administration is highly discouraged due to additive negative inotropic and chronotropic effects.
Antineoplastic drugs metabolized via CYP3A4 and/or P-glycoprotein — diltiazem may alter their pharmacokinetics and exacerbate cardiotoxicity.
Immunosuppressants — diltiazem inhibits CYP3A4 and P-glycoprotein, potentially increasing blood concentrations of immunosuppressants; close monitoring and dose adjustments are required.

Why does diltiazem have low bioavailability despite good GI absorption?

This is a classic example of presystemic metabolism (first-pass effect). The drug is readily absorbed in the gut, but during its initial passage through the liver, a large fraction is degraded by enzymes before reaching the systemic circulation. This distinguishes it from drugs whose concentration drops due to renal clearance or protein binding.

What is the main pharmacokinetic difference between diltiazem and verapamil?

The key difference lies in the onset of action. Diltiazem acts significantly faster—within 30 minutes of administration. Its half-life is 3–4 hours, and it is eliminated primarily through the gastrointestinal tract.

How do the adverse effects of diltiazem and verapamil differ?

Despite similar mechanisms of action (cardiac and vascular effects) and shared indications (angina, arrhythmias), their adverse reactions differ. Diltiazem is characterized by tachycardia, hypotension, edema, headaches, and muscle cramps. Verapamil, by contrast, more commonly causes bradycardia, AV block, and constipation.

Go deeper

Presystemic drug metabolism (first-pass hepatic effect).
Comparative pharmacodynamics of verapamil, amlodipine, and nifedipine.
Mechanisms of peripheral edema development with vasoselective drugs.
Pharmacological management of arrhythmias and angina: drug selection.
Routes of drug elimination: fecal excretion versus renal clearance.